These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34318603)

  • 1. Nodal metabolic tumour volume on baseline
    Alipour R; Bucknell N; Bressel M; Everitt S; MacManus M; Siva S; Hofman MS; Akhurst T; Hicks RJ; Iravani A
    J Med Imaging Radiat Oncol; 2021 Oct; 65(6):748-754. PubMed ID: 34318603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
    Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volumetric parameters from [
    Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
    J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.
    Iravani A; Turgeon GA; Akhurst T; Callahan JW; Bressel M; Everitt SJ; Siva S; Hofman MS; Hicks RJ; Ball DL; Mac Manus MP
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1869-1877. PubMed ID: 31190177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC.
    Agüloğlu N; Aksu A; Unat DS; Akyol M
    Nucl Med Commun; 2022 Dec; 43(12):1217-1224. PubMed ID: 36345766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
    Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What
    Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of metabolic parameters measured by
    Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
    J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
    Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
    Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of Independent Prognostic Value of Asphericity of
    Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
    Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.